• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕博利珠单抗联合药理剂量维生素C治疗平滑肌肉瘤

Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma.

作者信息

Rieth John M, Belzer Alex C, Walhof Mackenzie L, Milhem Mohammed M

机构信息

Division of Hematology, Oncology, and Blood and Marrow Transplantation, University of Iowa, Iowa City, IA, USA.

Carver College of Medicine, University of Iowa, Iowa City, IA, USA.

出版信息

Case Rep Oncol. 2024 Aug 21;17(1):906-912. doi: 10.1159/000539979. eCollection 2024 Jan-Dec.

DOI:10.1159/000539979
PMID:39474533
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11521403/
Abstract

INTRODUCTION

Leiomyosarcoma (LMS) is a malignancy with smooth muscle differentiation. Metastatic LMS is associated with poor prognosis and limited efficacy of systemic treatment. Novel treatment modalities are desperately needed for this entity.

CASE PRESENTATION

We report the first use of pembrolizumab plus pharmacologic ascorbate in 3 patients with metastatic LMS. All cases resulted in persistent objective responses and disease control significantly better than has been reported with chemotherapy or other immunotherapeutic approaches. Three patients with metastatic LMS, one each of uterine, vascular, and soft tissue origin, were treated with pembrolizumab plus pharmacologic ascorbate. The patient with uterine LMS received combination therapy at presentation and had persistent response for 12 months, which is ongoing. The patient with metastatic LMS of the inferior vena cava received combination therapy at presentation and had persistent response for 12 months, at which time new metastases were found. The patient with soft tissue LMS had disease progression on pembrolizumab monotherapy prior to the addition of ascorbate, after which she had a 17-month response, which is ongoing. No side effects attributed to treatment were reported.

CONCLUSION

Pembrolizumab plus pharmacologic ascorbate is a novel immunotherapeutic approach and warrants further study in LMS.

摘要

引言

平滑肌肉瘤(LMS)是一种具有平滑肌分化的恶性肿瘤。转移性LMS预后较差,全身治疗效果有限。该疾病迫切需要新的治疗方式。

病例报告

我们报告了3例转移性LMS患者首次使用帕博利珠单抗联合药理剂量维生素C的情况。所有病例均产生了持续的客观反应,疾病控制情况明显优于化疗或其他免疫治疗方法所报告的情况。3例转移性LMS患者,分别起源于子宫、血管和软组织,接受了帕博利珠单抗联合药理剂量维生素C的治疗。子宫LMS患者初诊时接受联合治疗,持续缓解12个月,目前仍在持续缓解中。下腔静脉转移性LMS患者初诊时接受联合治疗,持续缓解12个月,此时发现了新的转移灶。软组织LMS患者在加用维生素C之前接受帕博利珠单抗单药治疗时病情进展,加用后缓解了17个月,目前仍在持续缓解中。未报告与治疗相关的副作用。

结论

帕博利珠单抗联合药理剂量维生素C是一种新的免疫治疗方法,值得在LMS中进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4287/11521403/e3970683543c/cro-2024-0017-0001-539979_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4287/11521403/e3970683543c/cro-2024-0017-0001-539979_F01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4287/11521403/e3970683543c/cro-2024-0017-0001-539979_F01.jpg

相似文献

1
Pembrolizumab plus Pharmacologic Ascorbate in the Treatment of Leiomyosarcoma.帕博利珠单抗联合药理剂量维生素C治疗平滑肌肉瘤
Case Rep Oncol. 2024 Aug 21;17(1):906-912. doi: 10.1159/000539979. eCollection 2024 Jan-Dec.
2
PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates.PD-1 抑制转移性高肿瘤突变负荷(TMB)平滑肌肉瘤及其临床病理相关性。
BMJ Case Rep. 2023 Nov 17;16(11):e256697. doi: 10.1136/bcr-2023-256697.
3
Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.曲贝替定联合多柔比星治疗晚期子宫或软组织平滑肌肉瘤(LMS-02):一项非随机、多中心、2 期临床试验。
Lancet Oncol. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.
4
Leiomyosarcoma of the Inferior Vena Cava with Hepatic and Pulmonary Metastases: Case Report.下腔静脉平滑肌肉瘤伴肝肺转移:病例报告
J Radiol Case Rep. 2019 May 31;13(5):30-40. doi: 10.3941/jrcr.v13i5.3641. eCollection 2019 May.
5
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.多柔比星单药与多柔比星联合曲贝替定序贯曲贝替定单药一线治疗转移性或不可切除平滑肌肉瘤(LMS-04):一项随机、多中心、开放标签 3 期临床试验。
Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.
6
"Low-grade leiomyosarcoma" and late-recurring smooth muscle tumors of the uterus: a heterogenous collection of frequently misdiagnosed tumors associated with an overall favorable prognosis relative to conventional uterine leiomyosarcomas.“低度恶性平滑肌肉瘤”和子宫晚发复发性平滑肌肿瘤:这是一组经常被误诊的异质性肿瘤,与传统的子宫平滑肌肉瘤相比,总体预后良好。
Am J Surg Pathol. 2011 Nov;35(11):1626-37. doi: 10.1097/PAS.0b013e31822b44d2.
7
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates.埃立布林联合帕博利珠单抗治疗转移性软组织肉瘤的 II 期研究:临床结果和生物学相关性。
Clin Cancer Res. 2024 Apr 1;30(7):1281-1292. doi: 10.1158/1078-0432.CCR-23-2250.
8
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study).吉西他滨单药对比吉西他滨联合多西他赛治疗转移性或复发性平滑肌肉瘤患者的多中心、分层随机二期研究:法国癌症中心联合会(FNCLCC)肉瘤协作组研究(TAXOGEM 研究)。
Oncologist. 2012;17(9):1213-20. doi: 10.1634/theoncologist.2011-0467. Epub 2012 Aug 20.
9
Targeting the Molecular and Immunologic Features of Leiomyosarcoma.针对平滑肌肉瘤的分子和免疫特征
Cancers (Basel). 2023 Mar 31;15(7):2099. doi: 10.3390/cancers15072099.
10
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas.转移性软组织肉瘤免疫治疗疗效的回顾性分析
Cancers (Basel). 2020 Jul 11;12(7):1873. doi: 10.3390/cancers12071873.

本文引用的文献

1
Pharmacological ascorbate as a novel therapeutic strategy to enhance cancer immunotherapy.药物性抗坏血酸作为一种增强癌症免疫疗法的新型治疗策略。
Front Immunol. 2022 Aug 22;13:989000. doi: 10.3389/fimmu.2022.989000. eCollection 2022.
2
Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.多柔比星单药与多柔比星联合曲贝替定序贯曲贝替定单药一线治疗转移性或不可切除平滑肌肉瘤(LMS-04):一项随机、多中心、开放标签 3 期临床试验。
Lancet Oncol. 2022 Aug;23(8):1044-1054. doi: 10.1016/S1470-2045(22)00380-1. Epub 2022 Jul 11.
3
Pharmacological ascorbate improves the response to platinum-based chemotherapy in advanced stage non-small cell lung cancer.
药物性抗坏血酸可改善晚期非小细胞肺癌对铂类化疗的反应。
Redox Biol. 2022 Jul;53:102318. doi: 10.1016/j.redox.2022.102318. Epub 2022 Apr 20.
4
Real-world experience with pembrolizumab in patients with advanced soft tissue sarcoma.帕博利珠单抗治疗晚期软组织肉瘤患者的真实世界经验。
Ann Transl Med. 2021 Feb;9(4):339. doi: 10.21037/atm-21-49.
5
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.多柔比星加达卡巴嗪、多柔比星加异环磷酰胺或多柔比星单独作为晚期平滑肌肉瘤的一线治疗:来自欧洲癌症研究与治疗组织软组织和骨肉瘤组的倾向评分匹配分析。
Cancer. 2020 Jun 1;126(11):2637-2647. doi: 10.1002/cncr.32795. Epub 2020 Mar 4.
6
High-dose vitamin C enhances cancer immunotherapy.大剂量维生素 C 增强癌症免疫疗法。
Sci Transl Med. 2020 Feb 26;12(532). doi: 10.1126/scitranslmed.aay8707.
7
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model.高剂量抗坏血酸与抗 PD-1 在淋巴瘤小鼠模型中协同作用。
Proc Natl Acad Sci U S A. 2020 Jan 21;117(3):1666-1677. doi: 10.1073/pnas.1908158117. Epub 2020 Jan 7.
8
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.含抗坏血酸的药物与吉西他滨联合用于转移性和淋巴结阳性胰腺癌(PACMAN)的控制:一项 I 期临床试验结果。
Cancer Chemother Pharmacol. 2013 Mar;71(3):765-75. doi: 10.1007/s00280-013-2070-8. Epub 2013 Feb 5.
9
Enhancement of natural killer cell activity and T and B cell function by buffered vitamin C in patients exposed to toxic chemicals: the role of protein kinase-C.缓冲型维生素C对接触有毒化学物质患者自然杀伤细胞活性以及T细胞和B细胞功能的增强作用:蛋白激酶C的作用
Immunopharmacol Immunotoxicol. 1997 Aug;19(3):291-312. doi: 10.3109/08923979709046977.